Following yesterday's approval of IND registration clinical license for MC-1-50, today, the application for clinical trial of C-13-60 cell preparation of Precision Biotech targeting CEA solid tumor was approved by National Medical Products Administration (NMPA).

From November 17th to 22nd, 2023, Professor Jesús Prieto, the overseas chief scientist of Precision Biotech, visited Chongqing at the key point where the CAR-T series drug development achievements of Precision Biotech broke out, and made a phased summary for overseas scientific research to assist Precision Biotech R&D transformation and upgrading, gather global scientific and technological resources and boost product development and application.

On November 10th,Precision Biotech today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for pCAR-19B

On November 6th, the first Belt and Road conference on scientific and technology exchange in China was held in Chongqing.

On October 16th, the release ceremony of the list of Top Ten Chongqing Science and Technology Innovation Figures of the Year in 2023 was held in the West Science City of Chongqing .

Recently, with its strong innovation ability and superior innovation achievements, Chongqing Precision Biotech was once again promoted to the Top 100 Pharmaceutical Innovation Enterprises in China in 2023 and won this honor for four consecutive years.

Recently, Chongqing Precision Biotech obtained the seventh IND acceptance for CAR-T products. This is the first IND officially applied for MC-1-50

The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was held on June 2-6, 2023. The details of three abstracts of clinical and preclinical research results of Chongqing Precision Biotech were published in ASCO official website. Two of them were selected into the conference report and one was included in the online publication.

On April 27th, seven enterprises, namely Chongqing Precision Biotech, Jinfeng Laboratory, Zien Biotechnology, Hygeia Hospital, Yucheng Company, Square One China Innovation Center and Western Venture Capital Center, established the Haizhi-Offshore Innovation and Entrepreneurship Alliance (hereinafter referred to as the Alliance) in Chongqing High-tech Zone of Western Science City

Recently, Chongqing Precision Biotech passed the comprehensive review by the Chongqing Food and Drug Administration and was approved for the Drug Production License of CAR-T cell therapy products, becoming the first in the western region and one of the few in the country to have this license from the same industry.